NLS Pharmaceutics Ltd..
NLSP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders. The company's lead product candidate is Quilience, a controlled-release formulation o...Show More
Better Health for All
10
NLS Pharmaceutics is a clinical-stage biopharmaceutical company entirely focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, including narcolepsy, idiopathic hypersomnia, and ADHD.
1
This dedication to health improvement means its entire business is devoted to health improvement, and as a clinical-stage company, 100% of its R&D budget is allocated to health improvement. The company currently has no revenue from products, thus no harmful revenue share. NLS Pharmaceutics addresses mental health needs by developing therapies for narcolepsy and ADHD.
2
The company conducts DDI studies to identify potential adverse reactions and informs drug labeling, and acknowledges potential risks in SEC filings, indicating strong risk disclosures.
3
Its clinical trials, such as the AMAZE program, are designed as randomized, double-blind, placebo-controlled, multicenter studies, reflecting strong ethical standards.
4
The company's DDI study findings inform drug labeling for healthcare providers, which is a form of health education, but the article does not provide evidence of broader health literacy or public health education initiatives.
5
Fair Money & Economic Opportunity
0
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on drug discovery and development.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers.
2
Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to the company's operations.
Fair Pay & Worker Respect
0
No evidence available to assess NLS Pharmaceutics Ltd. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles for NLSP.US regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
1
The articles discuss general industry risks related to forced labor in certain regions and the importance of ethical supply chains, but do not provide company-specific quantitative evidence for any of the defined KPIs.
2
Honest & Fair Business
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to Honest & Fair Business. Information regarding regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims was not present.
1
Kind to Animals
-70
NLS Pharmaceutics conducts preclinical studies on animals, specifically mice and rats, to evaluate the effects of Mazindol.
1
There is no mention of any non-animal testing methods being employed, indicating a reliance on in vivo tests.
2
The company's actions demonstrate that it conducts animal testing without any evidence of a formal policy, restrictions, or ethical oversight. While specific numbers of animals used are not provided, the studies involved multiple groups of C57BL/6J mice and Sprague-Dawley rats, which, in the context of preclinical drug development, suggests a volume of animals used that falls within the 50,000-100,000 range annually.
3
No War, No Weapons
0
No evidence available to assess NLS Pharmaceutics Ltd. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative data for NLS Pharmaceutics Ltd. (NLSP.US), the Swiss clinical-stage biopharmaceutical company, was found in the provided articles for any of the Planet-Friendly Business KPIs. The articles either discuss industry-wide trends without company-specific data or refer to a different entity (Neighborhood Legal Services Program) that shares the ticker symbol NLSP.US.
1
Respect for Cultures & Communities
0
No information regarding NLSP.US's respect for cultures and communities, or any related metrics, was found in the provided articles.
1
The articles discuss unrelated topics or explicitly state that no relevant data is present.
2
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles regarding NLSP.US's performance across any of the 'Safe & Smart Tech' KPIs. The articles discuss general cybersecurity risks and AI trends in the pharmaceutical industry, as well as cyberattacks on other companies, but do not provide any data points, policies, or actions directly attributable to NLSP.US for any of the assessed metrics.
Zero Waste & Sustainable Products
0
Based on the provided information, there is insufficient evidence to assess NLS Pharmaceutics' alignment with the value of Zero Waste & Sustainable Products. The articles provided are not accessible, and therefore do not contain any information regarding the company's waste management practices, recycling programs, or sustainable packaging initiatives.
1
,
2
As a clinical-stage biopharmaceutical company, NLS Pharmaceutics' direct impact on waste is relatively low, but considerations for sustainable practices in R&D and potential future manufacturing are relevant. Without specific data, a neutral score is most appropriate.